Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.61 |
| ▸ | BACE1 | P56817 | 13/20 | 0.60 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.60 |
| ▸ | CTSD | P07339 | 2/20 | 0.58 |
| ▸ | MME | P08473 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29802215 | 0.96 | BACE1 (0.57) | NAALAD2BACE1BACE2CTSDMME | |
| SCHEMBL29630475 | 0.96 | BACE1 (0.57) | NAALAD2BACE1BACE2CTSDMME | |
| SCHEMBL8821940 | 0.95 | NAALAD2 (0.64) | NAALAD2BACE1BACE2CTSDMME | |
| SCHEMBL27914476 | 0.95 | NAALAD2 (0.68) | NAALAD2BACE1BACE2MME | |
| SCHEMBL3748615 | 0.95 | NAALAD2 (0.68) | NAALAD2BACE1BACE2MME | |
| SCHEMBL3732243 | 0.95 | NAALAD2 (0.68) | NAALAD2BACE1BACE2MME | |
| SCHEMBL29602993 | 0.95 | NAALAD2 (0.68) | NAALAD2BACE1BACE2MME | |
| SCHEMBL2980529 | 0.95 | NAALAD2 (0.68) | NAALAD2BACE1BACE2MME | |
| SCHEMBL31134839 | 0.94 | BACE1 (0.57) | NAALAD2BACE1BACE2CTSDMME | |
| SCHEMBL29827935 | 0.94 | NAALAD2 (0.67) | NAALAD2BACE1BACE2CTSDMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12496292-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250108039-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2025-04-03 | — | — | US | disclosed |
| EP-3838298-B1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2025-02-26 | — | — | EP | disclosed |
| EP-4464384-A2 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | Purdue Research Foundation (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2024-04-04 | — | — | US | disclosed |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-11-02 | — | — | US | disclosed |
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2023-09-21 | — | — | US | disclosed |
| US-11758933-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2023-09-19 | — | — | US | disclosed |
| US-11717514-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230000836-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-01-05 | — | — | US | disclosed |
| US-11504357-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2022-11-22 | — | — | US | disclosed |
| US-20220361545-A1 | ENHANCED SALT COMPOSITIONS AND METHODS OF PREPARATION THEREOF | DOUXMATOK LTD (IL) | 2022-11-17 | — | — | US | disclosed |
| US-11369590-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2022-06-28 | — | — | US | disclosed |
| EP-3368542-B1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11357246-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| EP-3656403-B1 | PREPARATION PROCESS OF PSMA BINDING LIGAND-LINKER CONJUGATES | PURDUE RESEARCH FOUNDATION (US) | 2022-05-11 | — | — | EP | disclosed |
| US-11318121-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2022-05-03 | — | — | US | disclosed |
| US-11298341-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2022-04-12 | — | — | US | disclosed |
| US-20220096445-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | NAALAD2 49/4885BACE1 2024/4885BACE2 2155/4885 |
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | NAALAD2 1910/4885BACE1 4303/4885BACE2 4160/4885 |
| US-11298341-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | NAALAD2 49/4885BACE1 2024/4885BACE2 2155/4885 |
| US-20250108039-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | NAALAD2 49/4885BACE1 2024/4885BACE2 2155/4885 |
| US-12496292-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | NAALAD2 49/4885BACE1 2024/4885BACE2 2155/4885 |
| US-11369590-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | NAALAD2 49/4885BACE1 2024/4885BACE2 2155/4885 |
| US-11318121-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | NAALAD2 49/4885BACE1 2024/4885BACE2 2155/4885 |
| US-20220096445-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | NAALAD2 52/4885BACE1 2108/4885BACE2 2347/4885 |
| US-11357246-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | NAALAD2 1910/4885BACE1 4303/4885BACE2 4160/4885 |
| US-20230000836-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | NAALAD2 49/4885BACE1 2024/4885BACE2 2155/4885 |
| US-11504357-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | NAALAD2 49/4885BACE1 2024/4885BACE2 2155/4885 |
| US-11717514-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | NAALAD2 49/4885BACE1 2024/4885BACE2 2155/4885 |
| US-11758933-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | NAALAD2 1910/4885BACE1 4303/4885BACE2 4160/4885 |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | NAALAD2 49/4885BACE1 2024/4885BACE2 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.